Should I Buy NRXS? NRXS 2026 Analysis

Should You Buy Neuraxis Inc (NRXS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.650

1 Day change

-0.21%

52 Week Range

6.200

Analysis Updated At

2026/01/26

Neuraxis Inc (NRXS) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the stock has shown some positive price momentum and has bullish moving averages, the lack of significant trading signals, neutral insider and hedge fund activity, and mixed financial performance suggest a cautious approach. The company’s recent coverage expansion is a positive development, but the financials still show losses, and the technical indicators do not strongly support an immediate buy decision.

Technical Analysis

The stock has bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. However, the MACD histogram is negative (-0.0465) and contracting, and the RSI is neutral at 59.722. Key resistance levels are at 5.105 and 5.311, while support levels are at 4.441 and 4.235.

Options Data

Positive Catalysts

The company announced a significant coverage expansion with a large national payer, adding approximately 45M lives and unlocking significant pediatric opportunities. Analysts have raised the price target to $8 from $7, maintaining a Buy rating.

Neutral/Negative Catalysts

The stock has a 40% chance of declining by -3.89% in the next week based on candlestick analysis. Financials show a negative net income (-$2.32M) and declining EPS (-0.24). Gross margin also decreased by 2.5% YoY.

Financial Performance

In Q3 2025, revenue increased by 21.72% YoY to $811,414. However, net income remains negative at -$2.32M, though it improved by 28.97% YoY. EPS dropped by 4% YoY to -0.24, and gross margin decreased to 83.3%, down 2.5% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Craig-Hallum raised the price target to $8 from $7 and maintained a Buy rating, citing the company's coverage expansion as a significant growth opportunity.

1 Analyst Rating

Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.660

Low

Averages

High

Current: 4.660

Low

Averages

High

Craig-Hallum

Buy

maintain

$7 -> $8

AI Analysis

2025-12-22

Reason

Craig-Hallum

Price Target

$7 -> $8

AI Analysis

2025-12-22

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Neuraxis to $8 from $7 and keeps a Buy rating on the shares after the company announced that they have been included in coverage from a large, national payer. This coverage expansion adds approximately 45M lives, bringing total national coverage for IBStim to nearly 100M. The Anthem win adds coverage for as much as 20% of NeurAxis's pediatric opportunity, and the firm believes it really unlocks the opportunity itself.

Craig-Hallum

Chase Knickerbocker

Buy

initiated

2025-06-17

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

2025-06-17

initiated

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRXS

Unlock Now

NRXS Should I Buy

NRXS Should I Buy

Should You Buy Neuraxis Inc (NRXS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch